WeVote
Log In

Bill

Bill

HR 9972

To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.

119th Congress Introduced by Pete Sessions

HR 9972 would change how Medicare pays for skin substitute products, altering reimbursement method or rates under Title XVIII.

Introduced in House
0
WeVote Research Nonpartisan
Bill Summary · HR 9972

Overview

HR 9972 is a bill introduced in the 119th Congress with the stated aim of amending title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. The bill has at least one co-sponsor (Pete Sessions) and was referred to the House committees on Energy and Commerce and Ways and Means for consideration of provisions within their jurisdiction.

Primary purpose and intent

  • The core objective is to modify how Medicare pays for skin substitute products under the Medicare program (Title XVIII of the Social Security Act).
  • The change is framed as adjusting payment policy, which could involve how skin substitutes are priced, reimbursed, or classified for payment purposes.

Key provisions and changes (as described)

  • The bill explicitly amends Title XVIII of the Social Security Act. While the exact legislative text is not provided here, the core effect is to alter payment methodology or rates for skin substitute products covered under Medicare.
  • Potential areas the bill might address (common themes in similar proposals) include:
    • Reclassification of skin substitute products for reimbursement purposes.
    • Adjustment of payment caps, rates, or conversion factors specific to these products.
    • Clarifications of coverage criteria or coding to align payment with product use.
    • Methods to determine or update payment amounts (e.g., market-based pricing, inflation updates, or separate payment determinations).

Note: Specific numerical changes (percentages, dollar amounts, or schedule adjustments) are not provided in the summary available. The precise provisions would be found in the bill’s text.

Who is affected

  • Medicare beneficiaries who receive skin substitute products as part of their medical care, including in- or outpatient settings.
  • Healthcare providers and suppliers that furnish skin substitute products to Medicare beneficiaries (e.g., hospitals, outpatient facilities, clinicians, and distributors).
  • Medicare administrative contractors and entities responsible for processing Part A and Part B payments, since payment policy changes would affect reimbursement workflows and billing practices.
  • Payers and formulary decision-makers in settings where Medicare payment distinctions influence product selection.

Procedural and timeline aspects

  • Introduced in the House and assigned to:
    • Committee on Energy and Commerce
    • Committee on Ways and Means
  • The referral “for a period to be subsequently determined by the Speaker” indicates a standard process where committees will review the provisions and potentially propose amendments before moving to the floor for consideration.
  • There is no publicly stated timeline in the provided information regarding committee action, markup, or floor debate dates. Such milestones typically depend on committee schedules and House leadership decisions.

Potential implications

  • If enacted, the bill could alter the cost burden for Medicare, influence the choice of skin substitute products used in care, and modify provider reimbursement incentives.
  • The impact on patients could include changes in access, cost-sharing, or availability of certain products if payment rates affect coverage determinations.
  • Providers may need to adjust billing practices, coding, and inventory management to align with new payment rules.

Important caveat

  • The summary above reflects stated objectives and typical effects of such amendments. For precise details on the payment mechanism, rate changes, affected product categories, and implementation timelines, the full text of HR 9972 and any related committee reports or fiscal notes should be consulted.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.